SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION																			
					Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					ed pur	Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP OMB Number: 3235- Estimated average burden hours per response:			3235-0287 n 0.5	
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																			
1. Name and Address of Reporting Person [*] HERON ELAINE J					2. Issuer Name and Ticker or Trading Symbol <u>PALVELLA THERAPEUTICS, INC.</u> [5. Relationship of Reporting Person(s) to (Check all applicable)				son(s) to Iss 10% Ov	
(Last)	(F	(Middle)			PVLA]										(give title		Other (s below)		
C/O PALVELLA THERAPEUTICS, INC. 125 STRAFFORD AVENUE, SUITE 360						3. Date of Earliest Transaction (Month/Day/Year) 12/13/2024													
					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) WAYNE PA			19087											Form filed by One Reporting Person Form filed by More than One Reporting Person					I
(City) (State) (Zip)																			
			ole I - Nor							Dis	-	-			-				
1. Title of Security (Instr. 3)			2. Transa Date (Month/D			ear) E	2A. Deemed Execution Date if any (Month/Day/Yea		Code (Disposed	ties Acquired (A) I Of (D) (Instr. 3, 4		4 and Securitie Beneficia Owned F		es Fo ally (D Following (I)		Direct	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) o (D)	^{Pr} Pri	rice Reported Transact (Instr. 3		on(s)			(Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	re es ally g d ion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$13.6	12/13/2024			Α		24,700		(1)	1	12/13/2034	Common Stock	24,7	700	\$0	24,70	0	D	
Explanation	n of Respons	ses:								1									1

1. The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date.

Kathleen A. McGowan, Attorney-in-Fact

12/17/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.